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Differences in cartilage thickness change (baseline to 12M) between prospective
KRs and non-KRs
TFTJ MFTC LFTC MT LT cMF cLF
All (24-60M)
P crude 0.027 0.23 0.007 0.025 0.003 0.70 0.053
P adjusted 0.002 0.18 0.0002 0.004 0.003 0.98 0.002
AUC 0.64 0.56 0.66 0.61 0.65 0.53 0.60
"Earlier" (24&36M)
P crude 0.09 0.34 0.047 0.018 0.0003 0.98 0.28
P adjusted 0.003 0.162 0.0003 0.0005 0.0002 0.72 0.021
AUC 0.69 0.60 0.68 0.71 0.74 0.53 0.54
"Later" (48&60M)
P crude 0.12 0.53 0.10 0.47 0.54 0.56 0.049
P adjusted 0.13 0.32 0.12 0.55 0.65 0.35 0.056
AUC 0.59 0.53 0.63 0.52 0.57 0.52 0.64
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S249score of these two lesions was associated with total WOMAC pain,
stiffness and dysfunction. Furthermore, popliteal cyst and sub-
gastocnemius bursa were signiﬁcantly associated with cartilage defects
in all compartments, and with radiographic osteophyte and MRI-
detected BMLs in medial tibiofemoral compartment. Longitudinally,
both baseline popliteal cyst (OR¼2.67 and 3.82 for medial tibial and
medial femoral, respectively, p<0.01) and total score of sub-
gastrocnemius bursa and popliteal cyst(OR¼2.15 and 2.91 for medial
tibial and medial femoral, respectively, p<0.01) were positively asso-
ciated with an increase in medial tibiofemoral cartilage defect. Baseline
popliteal cyst was also positively associated with an increase in BML
score before and after adjustment.
Conclusions: Popliteal cyst and subgastrocnemius bursa are associated
with not only symptoms, but also radiographic and MRI-detected
abnormalities of knee OA, suggesting that these cystic lesions may play
a pathological role in OA.
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Purpose: This study aimed at exploring the effects of commonly used
medication for the treatment of knee osteoarthritis (OA) on the
progression of the disease over a period of 24 consecutive months.
Methods: Participants were from the Osteoarthritis Initiative progres-
sion cohort (http://www.oai.ucsf.edu/) (n¼1,390) who met the
following criteria: 24 consecutive months of follow-up with complete
medical history, knee X-rays and MRI of the most symptomatic knee
(greatest WOMAC pain) at 0, 12 and 24 months, and who had no total
knee replacement during the follow-up. Using these criteria, 600
participants were found eligible. The knee radiograph data for joint
space width (JSW) and narrowing (JSN) were analyzed (OAI database)
and cartilage volume was assessed using fully-automated quantitative
magnetic resonance imaging as published.
Results: Of the 600 participants, 300 received continuous treatment for
24 months with commonly used pharmacological agents for OA
(NSAIDs, analgesics, etc., starting at least 1 month before baseline) with
or without () an OA slow acting drug (SYSADOA), namely glucos-
amine/chondroitin sulfate (Glu/CS, starting at least 6 months before
baseline). The other 300 had no OA treatment but could have received
the Glu/CS. The groups were named as follows: treated (OA treatment
Glu/CS) and untreated (no OA treatment  Glu/CS). The two groups
were balanced with the exception of a greater number of males (55% vs.
40%, p¼0.002) and higher body mass index (315 vs. 294, p¼0001)
and WOMAC scores (p<0.0001), as well as smaller JSW (3.431.89 vs.
3.801.70, p¼0.013) and greater Kellgren-Lawrence grade (p¼0.006) in
the treated vs. untreated group at baseline. The global knee cartilage
volume was not signiﬁcantly different between the two groups
(12.853.31 vs. 13.263.35 mm3). In the untreated group, less JSN at 12
months (+0.020.6 vs. ‑0.120.47, p¼0.057) and less cartilage volume
loss at 24 months in the medial central condyle (‑2.36.2 vs. ‑3.15.9,
p¼0.061) and plateau (‑2.36.7 vs. ‑4.28.5; p¼0.043) was found in
those taking the SYSADOA Glu/CS (n¼90) compared to those who were
not (n¼210). In the treated group, those who took the SYSADOA Glu/CS
(n¼113) had lower WOMAC scores at baseline (pain: 5.23.3 vs.
7.44.4, p<0.0001; stiffness: 2.81.5 vs. 3.21.9, p¼0.0373; disability:
16.110.4 vs. 21.314.0, p¼0.0004) compared to those who did not.
However, no differences in the changes in WOMAC scores were found
between the two subgroups over time. Among those who had a JSW at
baseline greater than the median (n¼148), the participants who
received Glu/CS presented smaller JSN at 12 (0.090.53 vs. ‑0.130.47,
p¼0.020) and 24 months (0.020.50 vs. ‑0.170.59, p¼0.092) and
demonstrated a statistically signiﬁcant reduction in cartilage volume
loss at 24 months in both the medial condyle (p¼0.01) and medial
compartment (p¼0.05) compared to those who did not.
Conclusions: Participants who received OA treatment showed more
severe disease symptoms and structural changes, which tended to
progress more rapidly over time. In both analyzed groups, those whotook Glu/CS had less symptoms and structural damage at baseline and
signiﬁcantly less JSN and cartilage volume loss over 24 months than
those who did not. The protective effect of Glu/CS on disease symptoms
and structural changes found in this observational study supports
results from previous studies.
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Purpose: In the absence of disease modifying OA therapy, knee
replacements (KR) are projected to increase to more than 3 million
annually in the US by 2030. Imaging biomarkers capable of predicting
relevant clinical endpoints with socioeconomic impact can be of
particular value for testing the efﬁcacy of disease modifying interven-
tions in clinical trials. The purpose of this prospective cohort study was
to explore whether baseline to 12M longitudinal changes in cartilage
thickness (MRI) differ between Osteoarthritis Initiative (OAI) partici-
pants who received a KR between 12 and 60M vs. those who did not
(non-KRs), and whether potential differences are greater for “earlier”
KRs (24-36M) than for “later” KRs (48-60M).
Methods: 532 right knees from the OAI cohort with deﬁnite radiographic
KOA (KLG2-4 central readings) were studied. Segmentation of weight-
bearing femorotibial cartilages was performed by 12 readers (Chondro-
metrics GmbH) with blinding to acquisition order, using baseline and
12M coronal FLASH water-excitation 3T images. Cartilage thickness
(ThCtAB) was determined in themedial (MFTC) and lateral compartment
(LFTC) and in tibial (MT/LT) and (weight-bearing) femoral cartilage (cMF/
cLF) plates, respectively. Unadjusted p-values (t-tests) and p-values
adjusted for age and baseline BMI and KLG (general linear model) were
used to identify differences in rates of cartilage thickness loss (baseline to
12M) between KR cases and non-cases, with sex and TKA status as ﬁxed
effects. Corresponding AUCs were computed using ROC analyses.
Results: Of the 532 participants (63% women, age 639y, BMI 304.8),
58% were KLG2 and 42% KLG3/4; 329 had medial>lateral JSN, 100 later-
al>medial, and 103medial¼lateral JSN. 7.5% (n¼40) received a femoroti-
bial KRwithin 4yrs; 18 at 24-36M (“earlier”), and a similarnumber (n¼22)
at 48-60M (“later”). One case with femoro-patellar KR was excluded. Of
the femorotibial KRs, 75%werewomen and 25% KLG2; KR cases displayed
amean KLG of 3.1 (33%with lateral involvement), whereas non-KR knees
were on average KLG 2.5 (19% lateral). KRs had thinner baseline femo-
rotibial cartilage(-15%; p¼2.0*E-6) than non-KRs, with differences similar
medially and laterally. Observed longitudinal cartilage thickness changes
between baseline and 12M were greater in KRs than in non-KRs in all
regions, differences reaching statistical signiﬁcance in the total femo-
rotibial joint, the lateral compartment, and in both tibiae (Table 1). The
lateral femur also showed signiﬁcant differences when adjusting for age,
BMI and KLG (Table 1). The discrimination between “earlier” KRs (24-
36M) vs. non KRswas stronger than that between “later” KRs (48M-60M)
vs. non KRs (Table 1).
